JP2002531415A5 - - Google Patents

Download PDF

Info

Publication number
JP2002531415A5
JP2002531415A5 JP2000584919A JP2000584919A JP2002531415A5 JP 2002531415 A5 JP2002531415 A5 JP 2002531415A5 JP 2000584919 A JP2000584919 A JP 2000584919A JP 2000584919 A JP2000584919 A JP 2000584919A JP 2002531415 A5 JP2002531415 A5 JP 2002531415A5
Authority
JP
Japan
Prior art keywords
epitope
leu
val
influenza virus
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000584919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531415A (ja
Filing date
Publication date
Priority claimed from IL12733198A external-priority patent/IL127331A0/xx
Application filed filed Critical
Publication of JP2002531415A publication Critical patent/JP2002531415A/ja
Publication of JP2002531415A5 publication Critical patent/JP2002531415A5/ja
Pending legal-status Critical Current

Links

JP2000584919A 1998-11-30 1999-11-28 ペプチドベースのインフルエンザ用ワクチン Pending JP2002531415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza
IL127331 1998-11-30
PCT/IL1999/000640 WO2000032228A2 (en) 1998-11-30 1999-11-28 Peptide-based vaccine for influenza

Publications (2)

Publication Number Publication Date
JP2002531415A JP2002531415A (ja) 2002-09-24
JP2002531415A5 true JP2002531415A5 (enExample) 2006-08-31

Family

ID=11072200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000584919A Pending JP2002531415A (ja) 1998-11-30 1999-11-28 ペプチドベースのインフルエンザ用ワクチン

Country Status (15)

Country Link
US (3) US6740325B1 (enExample)
EP (2) EP1135159A2 (enExample)
JP (1) JP2002531415A (enExample)
KR (1) KR100703571B1 (enExample)
AT (1) ATE556719T1 (enExample)
AU (1) AU766883B2 (enExample)
BR (1) BR9915811A (enExample)
CA (1) CA2352454C (enExample)
DK (1) DK2204187T3 (enExample)
ES (1) ES2389611T3 (enExample)
HK (1) HK1040620A1 (enExample)
IL (3) IL127331A0 (enExample)
NZ (1) NZ511918A (enExample)
PT (1) PT2204187E (enExample)
WO (1) WO2000032228A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU2002223398A1 (en) * 2000-08-10 2002-04-08 Tsinghua University A vaccine for influenza virus and its preparation
FI20031536A0 (fi) * 2003-10-20 2003-10-20 Biotie Therapies Oyj Korkean affiniteetin ligandit influenssavirukselle ja menetelmät niiden valmistamiseen
DK1692265T3 (da) 2003-11-04 2011-11-21 Univ Tulane Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
WO2006074303A2 (en) * 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
MY157941A (en) 2005-01-19 2016-08-15 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
FI20060200A0 (fi) * 2005-04-20 2006-02-27 Glykos Finland Oy Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi
MX2007015105A (es) * 2005-06-01 2008-03-18 Variation Biotechnologies Inc Formulacion de vacuna de influenza a base de peptido.
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US7468187B2 (en) * 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
WO2007051036A2 (en) * 2005-10-26 2007-05-03 Protelix, Inc. Influenza combinatorial antigen vaccine
US9533036B2 (en) * 2005-11-07 2017-01-03 Microvax, Llc Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein
AU2006322907B2 (en) * 2005-12-06 2012-08-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
HUE049580T2 (hu) * 2006-01-27 2020-09-28 Seqirus Uk Ltd Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
ES2534332T3 (es) * 2006-03-07 2015-04-21 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
WO2008002663A2 (en) * 2006-06-28 2008-01-03 The Board Of Trustees Of The Leland Stanford Junior University Immunogenic protein constructs
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
EP2139908A4 (en) 2007-03-12 2011-02-16 Antigen Express Inc REMOVAL OF PROTEIN Li INVOLVED IN Li-RNAi CONSTRUCTIONS IN ANTICANCER IMMUNOTHERAPY
JP5654345B2 (ja) 2007-08-02 2015-01-14 ビオンドヴァックス ファーマシューティカルズ リミテッド 多量体マルチエピトープインフルエンザワクチン
CA2721246A1 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
CA2721800A1 (en) 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
WO2009135152A2 (en) 2008-05-02 2009-11-05 University Of Rochester Arrayed detector system for measurement of influenza immune response
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
ES2573427T3 (es) 2009-07-06 2016-06-07 Variation Biotechnologies Inc. Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CN107296792B (zh) 2011-01-13 2021-07-27 变异生物技术公司 囊泡及由其产生之制剂的制备方法
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
CA2840982C (en) 2011-07-06 2022-06-07 Vira BITKO Human respiratory syncytial virus vaccine
WO2013028738A1 (en) 2011-08-22 2013-02-28 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
EP2780350B1 (en) 2011-11-18 2019-03-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
KR20140099828A (ko) 2013-02-05 2014-08-13 닛토덴코 가부시키가이샤 점막 투여용 백신 조성물
EP2762152A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
CN103961306A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮给予用疫苗组合物
EP3662927A3 (en) 2013-02-05 2020-10-21 Nitto Denko Corporation Vaccine composition
RU2697443C2 (ru) 2013-02-05 2019-08-14 Нитто Денко Корпорейшн Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
US10206985B2 (en) 2013-02-05 2019-02-19 Nitto Denko Corporation WT1 peptide cancer vaccine composition for mucosal administration
RU2014102948A (ru) * 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для мукозального введения
CN103961698A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮或粘膜给予用疫苗组合物
CA2841016A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
US20140220100A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
RU2531235C2 (ru) 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
CN103901202B (zh) * 2014-04-04 2015-08-12 中国人民解放军成都军区疾病预防控制中心 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法
US10925936B2 (en) 2014-09-03 2021-02-23 Nitto Denko Corporation Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates
EP3189852B1 (en) 2014-09-03 2021-04-07 Nitto Denko Corporation Bisphosphonate-containing pharmaceutical vaccine composition for humoral immunity
US11278616B2 (en) 2015-08-06 2022-03-22 Nitto Denko Corporation Immunity induction promoting composition, and vaccine pharmaceutical composition
WO2018126060A1 (en) * 2016-12-28 2018-07-05 Invvax, Inc. Influenza vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
AU3036597A (en) * 1996-05-21 1997-12-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza

Similar Documents

Publication Publication Date Title
JP2002531415A5 (enExample)
HK1040620A1 (zh) 治疗流感的肽基疫苗
Schild et al. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide.
Sambhara et al. Heterosubtypic Immunity against Human Influenza A Viruses, Including Recently Emerged Avian H5 and H9 Viruses, Induced by FLU–ISCOM Vaccine in Mice Requires both Cytotoxic T-Lymphocyte and Macrophage Function
JP2001523729A5 (enExample)
McMichael et al. The human cytotoxic T cell response to influenza A vaccination
JP2019500327A5 (enExample)
WO2003076603A3 (en) Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
JP2007505033A5 (enExample)
JP2004509149A5 (enExample)
ES2178943B1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
JP2005516885A5 (enExample)
IL209968A (en) Active Immune System Contains Myc Defragmenter Protein with a Conjugating Peptide
WO2003083058A3 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
JP2005237328A5 (enExample)
BR0211198A (pt) Composições farmacêuticas e seu uso
ZA936629B (en) Potentiation of immunogenic response
JP2020505335A5 (enExample)
JP2010506926A5 (enExample)
RU2017129340A (ru) Композиции nеisseria мeningitidis и способы их получения
JP2018501322A5 (enExample)
CA2352777A1 (en) Preparations containing virus-like particles as immunopotentiators administered through the mucosa
Andrew et al. Efficacy of influenza haemagglutinin and nucleoprotein as protective antigens against influenza virus infection in mice
JP2014520867A (ja) ジクロフェナクおよびチオコルチコシドを含有する貼付剤
WO2003099214A3 (en) Biguanide formulations